Antimalarial drug discovery - the path towards eradication.
about
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malariaA triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor (DSM421) with improved drug-like properties for treatment and prevention of malariaWorking towards consensus on methods used to elicit participant-reported safety data in uncomplicated malaria clinical drug studies: a Delphi technique study.Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.Evaluation of aminohydantoins as a novel class of antimalarial agents.Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum.A male and female gametocyte functional viability assay to identify biologically relevant malaria transmission-blocking drugsTriaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactionsStrand-specific RNA sequencing in Plasmodium falciparum malaria identifies developmentally regulated long non-coding RNA and circular RNA.Discovery of Dual-Stage Malaria Inhibitors with New Targets.A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments.Validation of a chloroquine-induced cell death mechanism for clinical use against malariaSafety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria TransmissionDiscovery of pyridyl-based inhibitors of Plasmodium falciparum N-myristoyltransferaseSubstrate and Inhibitor Specificity of the Plasmodium berghei Equilibrative Nucleoside Transporter Type 1Current therapies and future possibilities for drug development against liver-stage malaria.Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial ActivityNew paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections.Aminoacyl-tRNA synthetases as drug targets in eukaryotic parasites.Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance.Novel drug discovery for Chagas disease.Salinomycin and other ionophores as a new class of antimalarial drugs with transmission-blocking activity.Effect of piplartine and cinnamides on Leishmania amazonensis, Plasmodium falciparum and on peritoneal cells of Swiss mice.Improved antiparasitic activity by incorporation of organosilane entities into half-sandwich ruthenium(II) and rhodium(III) thiosemicarbazone complexes.Evaluation of the metabolism, bioactivation and pharmacokinetics of triaminopyrimidine analogs toward selection of a potential candidate for antimalarial therapy.Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria.Cyclopalladated organosilane-tethered thiosemicarbazones: novel strategies for improving antiplasmodial activity.Design and Synthesis of Terephthalic Acid-Based Histone Deacetylase Inhibitors with Dual-Stage Anti-Plasmodium Activity.Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission.
P2860
Q27644391-4BCDF8F7-8D3C-43DB-B330-EF51D4BFCF7CQ27728080-184A9C2D-0113-4724-98AE-ACF398C0FC0DQ30836732-467A3272-D026-4017-BCD4-BE66213C51F7Q33599811-2BBFC016-DA42-4B47-82D9-F1115B345B37Q33636531-615C4A09-F4A9-4681-BF65-6528CFC41A51Q33891625-8C8C8DF7-C2E3-4F83-A644-BD403B22FDDDQ34597517-1F02B104-6D53-4D54-A8DF-39907456D34DQ35311620-C0716AAE-D6F8-4DF8-A48B-E1E690BF6703Q35592537-727FD97F-FC86-431B-A64A-39FAF2BE535AQ35662591-6FB842F3-2341-4F3C-91FC-699B0EDEC494Q35868585-4E2C8700-7073-45D4-8994-6BC65201AAB0Q36137064-4611335C-0554-4617-8387-04ED7F2C9B4EQ36179646-4B3E1915-63B2-406F-985D-B0118C239139Q36215894-3A6DE34C-6183-4671-B145-C056F0E7B563Q36591461-CDA55794-91C0-4D27-B12A-52FD1F6EBBFDQ36947737-6A320423-08C5-47E7-B3D4-DDB7F9DDBEA4Q36951722-97AB201E-C251-4ADB-96C9-43D4FF1B5107Q36996257-E2046A9C-0320-4EEE-B6B9-EC0777197C4BQ37093155-A03F95E1-09D0-4029-A531-A6AEAD56408AQ37613101-F7F725ED-5752-4AA0-AAC9-8D242C4B5FEAQ38399949-403A3B8F-E6B7-4025-B565-547F4CC2606DQ38770142-07CA0277-037B-4A29-8E64-3A9EB0FD24A5Q38866063-7F1FCAD2-714B-4881-BC44-A4EF5D740EA8Q38878704-D59939CC-8D39-4C36-A22A-DCE5E62C3176Q38923200-1E616A84-27D8-44F2-874A-3310F655E498Q40501587-0181AB04-C640-4C5F-AC13-B4AA3C8C31CEQ41588963-388E7CA1-61CD-487B-8FCB-25EEABD2F717Q41915664-9888FB52-C19E-41BE-BDFA-18E8A4F4B573Q46124569-C788A18A-5097-46D6-B52E-AC6F401A20CFQ47096821-97C5514B-8EF8-48CD-B107-ED31321D0308
P2860
Antimalarial drug discovery - the path towards eradication.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antimalarial drug discovery - the path towards eradication.
@en
Antimalarial drug discovery - the path towards eradication.
@nl
type
label
Antimalarial drug discovery - the path towards eradication.
@en
Antimalarial drug discovery - the path towards eradication.
@nl
prefLabel
Antimalarial drug discovery - the path towards eradication.
@en
Antimalarial drug discovery - the path towards eradication.
@nl
P2093
P2860
P921
P1433
P1476
Antimalarial drug discovery - the path towards eradication
@en
P2093
Brice Campo
David Waterson
Didier Leroy
Emilie Burlot
Paul Willis
Sarah Jeanneret
Stephanie Cherbuin
Thomas Spangenberg
P2860
P304
P356
10.1017/S0031182013000826
P5008
P577
2013-07-17T00:00:00Z